abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

pharmafile | May 20, 2019 | News story | Research and Development, Sales and Marketing |  AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure 

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed glioblastoma (GBM) in patients whose tumours have epidermal growth factor receptor (EGFR) amplification, after it was identified in an interim analysis that the therapy presented no survival benefit to patients.

The disappointing news comes after an Independent Data Monitoring Committee (IDMC) discovered that the drug, when combined with the standard regimen of radiation and temozolomide, lacked survival benefit compared to placebo, and thus recommended that the trial be stopped.

“Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers,” explained Dr Michael Severino, Vice Chairman and President at AbbVie.

Advertisement

The company also announced that enrolment has been placed on hold for all ongoing studies involving Depatux-M.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

QV Bioelectronics, a medtech business specialising in implants for cancer treatment, has announced that it …

The Gateway to Local Adoption Series

Latest content